Tumor infiltrating lymphocyte recruitment in patients with early stage breast cancer after intramammary IRX-2 cytokine immunotherapy von Page, David B., Pucilowska, Joanna, Berinstein, Neil Lorne, Egan, James E.

Volltext

A phase 2 clinical trial testing DPX-Survivac and metronomic low dose cyclophosphamide as immunotherapy for patients with recurrent diffuse large b-cell lymphoma von Berinstein, Neil Lorne, Van Der Jagt, Richard H. C., Cheung, Matthew C., Buckstein, Rena, Karkada, Mohan, Quinton, Tara, MacDonald, Lisa, Stanford, Marianne, Nigam, Rita, Mansour, Marc

Volltext

Determination of optimal dose and treatment schedule of the immunotherapeutic vaccine, DPX-Survivac, for combination immunotherapy treatment of ovarian, fallopian tube or peritonea... von Villella, Jeannine A., Wilson, Michelle K., Berinstein, Neil Lorne, Karkada, Mohan, Quinton, Tara, Butler, Marcus O., Lheureux, Stephanie, Mandilaras, Victoria, Dhani, Neesha C., Weir, Genevieve, MacDonald, Lisa, Nigam, Rita, Stanford, Marianne, Mansour, Marc, Oza, Amit M.

Volltext

Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer von Villella, Jeannine A., Wilson, Michelle K., Berinstein, Neil Lorne, Brown, Jennifer, Lheureux, Stephanie, Butler, Marcus O., Ramsahai, Janelle, Odunsi, Kunle, Karkada, Mohan, Nemunaitis, John J., Morse, Michael, Pejovic, Tanja, Bentley, James, Weir, Genevieve, MacDonald, Lisa, Stanford, Marianne, Burzykowski, Tomasz, Nigam, Rita, Mansour, Marc, Oza, Amit M.

Volltext

Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients von Berinstein, Neil Lorne, Karkada, Mohan, Nigam, Rita, Morse, Michael, Nemunaitis, John J., Chatta, Gurkamal S., Kaufman, Howard, Odunsi, Kunle, Weir, Genevieve, MacDonald, Lisa, Stanford, Marianne, Mansour, Marc

Volltext

Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study von Berinstein, Neil Lorne, Oza, Amit M., Odunsi, Kunle, Karkada, Mohan, Villella, Jeannine A, Nemunaitis, John J., Morse, Michael, Pejovic, Tanja, Bentley, James, Nigam, Rita, Weir, Genevieve, MacDonald, Lisa, Stanford, Marianne, Burzykowski, Tomasz, Mansour, Marc

Volltext

Phase I/Ib clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC) von Wilson, Michelle, Villella, Jeannine A., Berinstein, Neil Lorne, Brown, Jennifer, Lheureux, Stephanie, Haley, Anna, Odunsi, Kunle, Karkada, Mohan, Nemunaitis, John J., Morse, Michael, Pejovic, Tanja, Bentley, James, Weir, Genevieve, MacDonald, Lisa, Sammatur, Leeladhar, Stanford, Marianne, Burzykowski, Tomasz, Nigam, Rita, Mansour, Marc, Oza, Amit M.

Volltext